Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by bazooka73on Dec 29, 2016 4:55pm

170 Views

Post# 25651585

RE:RE:RE:RE:RE:RE:RE:Dec.8 news release wtf?

3burtc wrote: Then mgmt should explain why the nr just before term sheets. This doesn't make any sense that they would issue a news release MIN./DAYS before they had actual news. Why would they not wait for the news and then issue the nr? Information has to IMPROVE!

Hey, of course the news release did make sense. just because they release a CEO update every have year in June and December. So why should they make an exemption?
There are so many guys here complaining about the lack of informationen from Sirona within the last months. But as soon as they get that, it isn't fine either.
If the go for a deal, the will let you all know for sure. And packing it in another news release won't harm.

Bullboard Posts

Changing Europe’s dependency on HREE from China